Status:
COMPLETED
A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with C...
Eligibility Criteria
Inclusion
- Must have a body mass index between 18 and 33 kg/m2 (inclusive)
- Adult female of nonchildbearing potential or male, any race or ethnicity, and in good health as determined by the medical history, physical exam, vital signs, 12-lead electrocardiogram, and clinical laboratory assessments
Exclusion
- Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion
- Any major surgery within 4 weeks of the first dose administration
- History of drug abuse within 2 years of the first dose administration
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
June 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 12 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT05389722
Start Date
June 9 2022
End Date
November 12 2022
Last Update
April 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Unit - Dallas
Dallas, Texas, United States, 75247-4968